Mirum Pharmaceuticals Inc (MIRM)
26.39
+0.55
(+2.13%)
USD |
NASDAQ |
May 06, 16:00
26.40
+0.01
(+0.04%)
After-Hours: 20:00
Mirum Pharmaceuticals Revenue (Quarterly): 69.55M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 69.55M |
| September 30, 2023 | 47.72M |
| June 30, 2023 | 37.50M |
| March 31, 2023 | 31.60M |
| December 31, 2022 | 27.91M |
| September 30, 2022 | 18.78M |
| Date | Value |
|---|---|
| June 30, 2022 | 17.48M |
| March 31, 2022 | 12.89M |
| December 31, 2021 | 3.138M |
| September 30, 2021 | 5.00M |
| June 30, 2021 | 11.00M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
3.138M
Minimum
Dec 2021
69.55M
Maximum
Dec 2023
25.69M
Average
18.78M
Median
Sep 2022
Revenue (Quarterly) Benchmarks
| Vanda Pharmaceuticals Inc | 45.27M |
| Sarepta Therapeutics Inc | 413.46M |
| Puma Biotechnology Inc | 43.77M |
| Reneo Pharmaceuticals Inc | -- |
| Tharimmune Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -35.66M |
| Total Expenses (Quarterly) | 102.14M |
| EPS Diluted (Quarterly) | -0.7095 |
| Enterprise Value | 1.261B |
| Gross Profit Margin (Quarterly) | 64.03% |
| Profit Margin (Quarterly) | -51.27% |
| Earnings Yield | -15.23% |
| Normalized Earnings Yield | -15.23 |